Silo Pharma Inc. (SILO), a developmental-stage biopharmaceutical company, on Monday announced plans to advance psychedelic-based therapies for treating mental health disorders, including SPC-15 in treating post-traumatic stress disorder, following an executive order by the U.S. government.
The executive order was issued on April 18, 2026, and directs multiple U.S. government agencies to accelerate research into psychedelic therapies and patient access to mental health treatments. Silo's lead program, SPC-15, is a novel serotonin 4 (5-HT4) receptor agonist formulated as an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). The nose-to brain administration system allows for rapid delivery to the central nervous system (CNS). The SPC-15 program is being advanced under a 505(b)(2) regulatory pathway, to enable a streamlined development timeline.
The company anticipates filing an investigational new drug (IND) application for SPC-15 with the U.S. Food and Drug Administration (FDA).
SILO closed Friday at $0.51, up 1.18%. In the premarket, shares are trading at $0.52, up 0.95%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.